On December 31, 2007, Raina, R.; Prawez, S.; Dimitrova, D. J.; Verma, P. K.; Pankaj, N. K. published an article.Product Details of 86393-32-0 The title of the article was Pharmacokinetics of ciprofloxacin following intravenous administration in WLH chickens (Gallus domesticus). And the article contained the following:
Pharmacokinetics of ciprofloxacin was studied in WLH chicken after single i.v. dose @ 4 mg.kg-1 body weight Plasma ciprofloxacin concentrations were analyzed by microbiol. assay technique using E. coli ATCC-25922 as test organisms grown. The determination of the best-fit compartment model and initial estimates of the model-dependent pharmacokinetics was analyzed for each bird by Top-Fit v. 2.0 computer program. The three compartment open model was the best fit for i.v. injection of ciprofloxacin. Statistical moments were also used to compute the noncompartmental pharmacokinetic anal. The elimination half life (t1/2β), volume of distribution from central compartment (Vc) and total body clearance (ClB) were 5.79±1.14 h, 0.85±0.07 L.kg-1 and 16.27±1.87mL.min-1.kg-1, resp. The mean residence time (MRT) and area under the plasma concentration vs time curve from 0 to ∞ (AUC0→ ∞) were 7.05±1.34 h and 4.54±0.59 μg.h.ml-1, resp. The variation coefficient of the technique for the intraassay and interassay precission was less than 10% in the range of standard concentration The lower limit of sensitivity of the ciprofloxacin assay was 0.015 μg.ml-1. The serum concentration at time zero (Cp°) and area under the curve from 0 to 24h (AUC0-24) were applied in the calculation of predictors of efficacy for concentration-dependent antibiotics. Ciprofloxacin concentration in plasma of chickens, maintaining min. inhibitory concentration (MIC <1 μg.ml-1) for upto 12 h after i.v. administration @ 4mg.kg-1, would be adequate for controlling avian bacterial diseases. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Product Details of 86393-32-0
The Article related to antimicrobial pharmacokinetics pharmacodynamics ciprofloxacin hydrochloride monohydrate escherichia pasteurella gallus, Pharmacology: Drug Metabolism and other aspects.Product Details of 86393-32-0
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics